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S U M M A R Y
Objectives: A randomized, double-blind, double-dummy, multicenter international study was conducted
to assess the clinical and bacteriologic response, safety, and compliance of a single 60-mg/kg dose of
azithromycin extended-release (ER) versus a 10-day regimen of amoxicillin/clavulanate 90/6.4 mg/kg
per day in children with acute otitis media at high risk of persistent or recurrent middle ear infection.
Methods: Children aged 3 to 48 months were enrolled and stratiﬁed into two age groups (24 months
and >24 months). Pretreatment tympanocentesis was performed at all sites and was repeated during
treatment at selected sites.
Results: The primary endpoint, clinical response at the test-of-cure visit in the bacteriologic eligible
population, was achieved in 80.5% of children in the azithromycin ER group and 84.5% of children in the
amoxicillin/clavulanate group (difference – 3.9%; 95% conﬁdence interval – 10.4, 2.6). Bacteriologic
eradication was 82.6% in the azithromycin ER group and 92% in the amoxicillin/clavulanate group
(p = 0.050). Children who received amoxicillin/clavulanate had signiﬁcantly higher rates of dermatitis
and diarrhea, a greater burden of adverse events, and a lower rate of compliance to study drug compared
to those who received azithromycin ER.
Conclusions: A single 60-mg/kg dose of azithromycin ER provides near equivalent effectiveness to a 10-
day regimen of amoxicillin/clavulanate 90/6.4 mg/kg per day in the treatment of children with acute
otitis media.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Acute otitis media (AOM) is a common infection of childhood,
with the ﬁrst episode frequently occurring in early infancy.1,2
Despite antibacterial therapy, this middle ear infection recurs in
about 20–30% of children.1–5 Persistence of the signs and
symptoms of AOM during antibacterial therapy and relapse within
1 month are both common.3–5 Children with recurrent or
persistent AOM are at increased risk of being infected with
penicillin-nonsusceptible Streptococcus pneumoniae or b-lacta-
mase-producing strains of Haemophilus inﬂuenzae.6–11
The macrolide antibiotic azithromycin is an option for the
treatment of AOM due to its in vitro activity against the most
common upper respiratory tract pathogens, including S. pneumo-§ Parts of this study were presented at the 45th Interscience Conference on
Antimicrobial Agents and Chemotherapy, December 16–19, 2005, Washington, DC,
USA and the 46th Interscience Conference on Antimicrobial Agents and
Chemotherapy, September 27–30, 2006, San Francisco, CA, USA.
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doi:10.1016/j.ijid.2010.12.003niae, H. inﬂuenzae, and Moraxella catarrhalis.12 Azithromycin
achieves good concentrations in middle ear ﬂuid.13–15 Pneumococ-
cal resistance has generally decreased due to the coverage of the 7-
valent pneumococcal vaccine; the only exception to this decreased
pneumococcal resistancewould be the increase in resistance caused
by the 19A serotype of pneumococcus, which is now included in the
recently released 13-valent S. pneumoniae conjugate vaccine.16,17
Dagan et al.18 recently reported that the increase in the number of
infections associated with this problematic S. pneumoniae serotype
19A was multifactorial and associated with the frequent use of oral
cephalosporinsand30-mg/kg regimensof azithromycin (twoagents
commonly used for the treatment of children with otitis media), as
well as the widespread use of the 7-valent S. pneumoniae conjugate
vaccine (which can lead to serotype replacement). However, the
newer 13-valent S. pneumoniae conjugate vaccine shoulddampenor
reverse this trend.
Single-dose therapy is particularly appropriate for children
requiring directly observed management or for whom compliance
maybepoor. Four clinical studieshavedemonstrated that single-dose
azithromycin (30 mg/kg) provides effective treatment for uncompli-
cated pediatric AOM due to H. inﬂuenzae,M. catarrhalis, Streptococcusses. Published by Elsevier Ltd. All rights reserved.
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against H. inﬂuenzae (a growing proportion of AOM infections) was
suboptimal.19 Double-tympanocentesis studies have shown that
failure to eradicate middle ear ﬂuid pathogens during therapy is
associated with a higher incidence of clinical failure and therapeutic
relapse.20,21 In previous double-tympanocentesis clinical trials
performed in children with AOM, lower rates of on-therapy
bacteriologic eradication and end-of-therapy clinical cures were
observed with a 5-day (30 mg/kg) azithromycin regimen compared
with 10 days of amoxicillin/clavulanate.22,23
As an alternative to standard azithromycin, an extended-release
(ER) microsphere formulation of the drug (azithromycin ER) was
administeredas a singledose andwaswell tolerated.24 The24-hAUC/
MIC ratio (the area under the concentration-time curve over 24 h
divided by the minimum inhibitory concentration) is the pharmaco-
kinetic parameter that best predicts the efﬁcacy of azithromycin;
therefore, itmakes sense to ‘front load’ thedose so that high levels are
achieved early in the course of infectionwhen the bacterial burden is
the greatest.25 In children, for whom a single 30-mg/kg dose of
conventional, immediate-release azithromycin already exists, the
microsphere technology allows for doublingof thedose (60 mg/kg) in
an effort to improve efﬁcacy without compromising tolerability.
The primary aim of this study was to evaluate the efﬁcacy and
safety of a single dose of azithromycin ER (60 mg/kg) with that of a
10-day, twice-daily regimen of amoxicillin/clavulanate (45/
3.2 mg/kg) in children with AOM who have, or are at risk for,
recurrent or persistent middle ear infection.
2. Methods
2.1. Study design
This was a randomized, double-blind, double-dummy, multi-
center, international study. The study was conducted in accor-
dance with the International Conference on Harmonization
Guidelines for Good Clinical Practice and the Declaration of
Helsinki. Ethical or institutional reviewboard approval of the study
was obtained at each participating center. Written informed
consent was obtained from parents or legal representatives of each
child before entering the study. The study utilized a non-inferiority
design to compare the efﬁcacy and safety of a single 60-mg/kg oral
dose of azithromycin ER (Pﬁzer Inc., New York, NY, USA) with that
of oral amoxicillin/clavulanate 90/6.4 mg/kg for 10 days. Non-
inferiority would be concluded if the lower limit of the 95%
conﬁdence interval (CI) around the difference in the primary
endpoint of clinical cure rates (azithromycin ERminus amoxicillin/
clavulanate) was greater than - 10%.
Children were stratiﬁed into two age groups (24 months and
>24 months) and randomized 1:1 within each stratum according
to a computer-generated permutated block code to receive either a
single 60-mg/kg oral dose of azithromycin ER on day 1 plus
amoxicillin/clavulanate placebo every 12 h on days 1 to 10 or oral
amoxicillin/clavulanate 45/3.2 mg/kg every 12 h on days 1 to 10
plus azithromycin ER placebo on day 1.
Children were assessed at baseline (day 1), at the on-treatment
(OT) visit (day 4–6), the test-of-cure (TOC) visit (day 12–14), and
the long-term follow-up (LTFU) visit (day 25–28). At two centers
(Costa Rica and the Dominican Republic), children with baseline
target AOM pathogens underwent a repeat tympanocentesis at the
OT visit and were evaluated at an additional end-of-study visit
(EOS) (day 41–64) to assess the recurrence of AOM.
2.2. Eligibility criteria
Male and female children between the ages of 3 and 48 months
were eligible for enrollment if they had clinical evidence of AOMand had, or were at risk for, recurrent or persistent AOM. The
diagnosis of AOMwas based on the presence of otalgia, ear fullness,
and/or purulent discharge due to an acute tympanic membrane
perforation, in association with two or more otoscopic signs of
middle ear ﬂuid, such as decreased or absent tympanic membrane
mobility (as assessed by pneumatic otoscopy), opaciﬁcation, or
yellow/white tympanic membrane discoloration. Also, children
had to have at least one indicator of acute inﬂammation such as ear
pain or marked redness or fullness/bulging of the tympanic
membrane.
The presence of middle ear ﬂuid was identiﬁed by EarCheck
PROTM spectral gradient level 3 or by tympanometry in children
aged < 6 months. Recurrent AOM was deﬁned as at least one
episode in the 30 days preceding enrollment, at least three
episodes in the previous 6 months, or at least four episodes in the
previous 12 months. Persistent AOMwas deﬁned as continuing for
48 h after starting a course of an oral antibacterial or occurring
7 days after completion of therapy. Risk of recurrent or persistent
AOM was determined by the presence of at least two of the
following factors: age <24 months; antimicrobial exposure within
the previous 6 months; ﬁrst episode of AOM during the ﬁrst 6
months of life; daycare attendance; and sibling or other household
contact aged <8 years. Therefore, a child could qualify for this
study based on a history of recurrent/persistent middle ear
infection, risk factors for recurrent/persistent middle ear infection,
or both.
2.3. Study populations
The primary study endpoint was clinical response assessed at
the TOC visit (12–14 days after the ﬁrst dose of study drug) in the
bacteriologic eligible population, deﬁned as clinically eligible
children with a baseline AOM pathogen (S. pneumoniae, H.
inﬂuenzae, M. catarrhalis, or S. pyogenes). Clinical per protocol
children were those who were clinically eligible, received 8 days
of study medication (active or placebo doses), received no
concomitant systemic antibiotic active against AOM pathogens,
and were assessed in the predeﬁned visit window. Bacteriologic
per protocol children were clinical per protocol children with a
baseline AOM pathogen. Bacteriologic OT children were bacterio-
logic eligible children who underwent repeat tympanocentesis at
the OT visit andwhose bacterial culture results were available. All-
treated children were those who were randomized and had
received at least one dose of study medication.
Secondary endpoints included clinical and bacterial response at
other visits and in other study populations, compliance, and safety
of both treatment regimens.
2.4. Clinical assessment
Clinical response was deﬁned as ‘cure’: resolution of signs and
symptoms of AOM or improvement requiring no further antimi-
crobial therapy; or ‘failure’: persistence of signs and symptoms of
AOM and the need for an additional antibacterial agent. In the non
per protocol populations, childrenwho did not return for follow-up
visits or who were not assessed within the predeﬁned windows
were classiﬁed as clinical failures. Children classiﬁed as clinical
cures at the TOC visit who developed AOM or who required an
additional antimicrobial between the TOC and the LTFU or EOS
visits were considered relapses.
Medical history, physical examination, otologic assessment
(tympanocentesis, pneumatic otoscopy, acoustic reﬂectometry,
hearing tests), and laboratory testing were performed at baseline
(day 1); clinical and otoscopic assessments were repeated at each
study visit. In children with a perforated tympanic membrane
<24 h before study entry, a swab of purulent discharge in the ear
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culture. Laboratory examinations were repeated at the TOC visit
and as needed thereafter in the case of clinically signiﬁcant
abnormal results. A mandatory second tympanocentesis was
performed at the OT visit at two selected sites. In addition, repeat
tympanocentesis was to be performed on children classiﬁed as
clinical failure or relapse at follow-up visits at all sites.
2.5. Bacteriologic assessment
At post-baseline visits, each pathogen was assigned a response
of eradication, presumed eradication, or persistence of the original
pathogen, except in those children at selected sites undergoing
mandatory tympanocentesis at the OT visit. In these children, only
eradication and persistence could be assigned for bacterial
outcome (i.e., outcome was not presumed). Superinfection was
deﬁned as the elimination of the original pathogen but the
emergence of a new target pathogen; these children were
considered bacteriologic failures.
Culture of middle ear ﬂuid or purulent discharge was performed
at local laboratories.b-LactamaseproductionbyH. inﬂuenzaeandM.
catarrhalis strains was assessed using CeﬁnaseTM discs (BD
Diagnostic Systems, Sparks, MD, USA) at ICON Laboratories (Farm-
ingdale, NY, USA andDublin, Ireland). This testingwas performedon
paired H. inﬂuenzae and M. catarrhalis isolates to determine
persistence or presence of different strains. Species conﬁrmation
and in vitro susceptibility testing of S. pneumoniae, H. inﬂuenzae,M.
catarrhalis, and S. pyogenes isolates were performed at a central
laboratory.MICsweredetermined bybrothmicrodilution according
to National Committee for Clinical Laboratory Standards (NCCLS)
guidelines.26 Breakpoints for H. inﬂuenzae were 4mg/ml for
azithromycin-susceptible (no breakpoints were available for
azithromycin-resistant) and 4mg/ml amoxicillin/2mg/ml clavu-
lanate for amoxicillin/clavulanate-susceptible and8mg/ml amox-
icillin/4mg/ml clavulanate for amoxicillin/clavulanate-resistant.
Susceptibilities of S. pneumoniae isolates to azithromycin (suscepti-
ble breakpoint0.5mg/ml; intermediate 1mg/ml; resistant2mg/
ml), to amoxicillin/clavulanate (susceptible breakpoint 2mg/ml;
intermediate 4mg/ml; resistant 8mg/ml), and to penicillin
(susceptible breakpoint 0.06mg/ml; intermediate 0.1–1mg/ml;
resistant 2mg/ml) were performed according to NCCLS proce-
dures. S. pyogenes breakpoints for azithromycin and amoxicillin/
clavulanate were the same as for S. pneumoniae; for penicillin, the
susceptible breakpoint was 0.12mg/ml. In this paper, the term
‘nonsusceptible’ includes the combination of isolates considered
‘resistant’ and ‘intermediate’.
Additional susceptibility testing of azithromycin-resistant S.
pneumoniae isolates (MIC >4 mg/ml) was conducted by Pﬁzer
Global Research and Development (PGRD) Ann Arbor Laboratories
(Ann Arbor, MI, USA). Genotyping of azithromycin-nonsusceptible
S. pneumoniae (ANSSP) isolates was conducted at PGRD Groton
Laboratories (Groton, CT, USA) for erythromycin ribosomal
methylase (erm) and macrolide efﬂux (mef) genes.27 Serotyping
of S. pneumoniae was performed at PGRD Groton using the
Pneumotest kit (Statens Serum Institut, Copenhagen, Denmark).
Pulsed-ﬁeld gel electrophoresis (PFGE) testing on paired isolates of
the same bacterial species collected at different study visits was
performed by Focus Technologies (Herndon, VA, USA) using the
protocol of Birren and Lai.28
2.6. Treatment compliance
The investigator directly observed compliance for the ﬁrst dose
of study medication. The investigator questioned the parents at
each visit to assess compliance with subsequent dosing. In
addition, parents were instructed to bring in their unused studymedication at the TOC visit. Adherence to all doses of study
medication, both active and placebo, was summarized, and
patients who took any portion of their prescribed dose were
considered compliant for that dose. Compliance summaries in the
all-treated and the bacteriologic eligible populations were based
on the percentage of patients who did or did not complete all
treatment as well as on the percentage of patients who completed
95%, 85%, or 50% of treatment. (Percent compliance equaled
doses prescribed minus doses missed divided by doses prescribed
times 100.)
2.7. Safety assessment
All children who received at least one dose of study medication
were assessed for safety and included in the all-treated study
population. This included a blood draw for chemistry and
hematology at the baseline and TOC visits, as well as monitoring
for adverse events (AEs). The investigator assessed the severity and
relationship of AEs to study medication at each visit. After
receiving the ﬁrst dose of azithromycin or placebo, children were
observed for 30 min for vomiting. The AE burden (AE days per
patient-year) was calculated for all-cause and treatment-related
AEs as follows: number of days of AEs divided by total observed
days for all-treated children/365.25.
2.8. Statistical analysis
The 95% CIs for age group-speciﬁc differences in cure rates were
constructed using the normal approximation to the binomial
distribution. For the primary analysis combining both age strata,
the 95% CI for the difference in cure rates was constructed using
weighted least squares with weights proportional to the reciprocal
of the age stratum speciﬁc variance.29–31 Data across sites were
pooled and no adjustments for sitewere applied. If specimenswere
obtained fromboth ears for a given visit, the ‘worst’ resultwas used
for the bacterial response (for example, a child from whom one
middle ear culture result was deemed ‘persistent’, and the other
‘eradicated’, would have ‘persistence’ as the bacterial response).
3. Results
The study was conducted between May 2003 and May 2004 at
60 outpatient sites in North America (n = 29), Europe (n = 20), and
Latin America (n = 11). Of 951 children screened, 923 were
randomized and 902 received azithromycin ER (n = 450) or
amoxicillin/clavulanate (n = 452). Patient disposition is shown in
Fig. 1. Baseline demographic and prognostic factors were similar
between the two treatment groups (Table 1).
3.1. Compliance
All children randomized to treatment with azithromycin ER
received their single dose of active treatment; 59% of children
randomized to amoxicillin/clavulanate received the full course of
20 doses. In the bacteriologic eligible population, 77% of children in
the amoxicillin/clavulanate arm were compliant with the full
course of treatment compared with 100% of children in the
azithromycin ER arm. Of the 91 childrenwho received less than the
full course of amoxicillin/clavulanate, none were excluded from
the clinical and bacteriological per-protocol populations due to
noncompliance.
3.2. Bacteriology at baseline
The overall number of pathogens isolated at baseline was
similar in both treatment groups (337 and 333, respectively). The
Bacteriologic Per Protocol
at TOC (n=239)
Bacteriologic Per Protocol
at LTFU (n=224)
Bacteriologic Per Protocol
at TOC (n=217)
Bacteriologic Per Protocol
at LTFU (n=195)
Analysis
Allocation
Patients randomized
(N = 923)
AZM (n=462)
Clinically evaluable/All treated (n=450)
Discontinued related to study drug:
Adverse event (n=9)
Lack of efficacy (n=33)
Discontinued not related to study drug:
Adverse event (n=4)
Other (n=4)
Patient defaulted (n=18)
No baseline pathogen (n=192)
Excluded: 
No TOC visit (n=38)
No LTFU visit (n=53)
Other* (n=15)
Safety (n=450)
CE at TOC (n=412)
CE at LTFU (n=382)
Bacteriologic Eligible (n=258)
AMC (n=461)
Clinically evaluable/All treated  (n=452)
Discontinued related to study drug:
Adverse event (n=5)
Lack of efficacy (n=25)
Discontinued not related to study drug:
Adverse event (n=5)
Other (n=9)
Patient defaulted (n=23)
No baseline pathogen (n=211)
Excluded:
No TOC visit (n=36)
No LTFU visit (n=55)
Other* (n=25)
Safety (n=452)
CE at TOC (n=409)
CE at LTFU (n=372)
Bacteriologic Eligible  (n=239)
Fig. 1. Patient disposition (AZM, extended-release azithromycin; AMC, amoxicillin/clavulanate; CE, clinically evaluable; LTFU, long-term follow-up; TOC, test of cure).
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catarrhalis, S. pyogenes, and Staphylococcus aureus (Table 2).
Target pathogens were present in middle ear ﬂuid in 282
(62.7%) all-treated children in the azithromycin ER group and 283
(62.6%) all-treated children in the amoxicillin/clavulanate group;
multiple pathogens were identiﬁed in 49 (10.9%) and 43 (9.5%)
children in each group, respectively. All H. inﬂuenzae isolates were
susceptible to azithromycin, and all but one were susceptible to
amoxicillin/clavulanate. A total of 25 (20.8%) S. pneumoniae
isolates in the azithromycin ER group were nonsusceptible to
azithromycin (MIC 1mg/ml) (ANSSP). In the amoxicillin/clavu-
lanate group, four (3.6%) were nonsusceptible to amoxicillin/
clavulanate (MIC 4 mg/ml). Among 23 baseline ANSSP in the
azithromycin ER group, four carried themef gene, eight carried the
ermB gene, and ﬁve carried themef + ermB genes. A combination of
either mef + ermA (n = 3) or ermB + ermTR (n = 3) genes was
identiﬁed in the remaining isolates. S. pyogenes was identiﬁed in
18 children in the azithromycin ER group and 13 children in the
amoxicillin/clavulanate group. All but one of the 31 isolates were
susceptible to azithromycin. Susceptibility testing of S. pyogenes toamoxicillin/clavulanate was performed for ﬁve isolates and all
were susceptible.
3.3. Clinical response
The primary efﬁcacy population, bacteriologic eligible children,
included 258 children in the azithromycin ER group and 239
children in the amoxicillin/clavulanate group. Table 3 shows the
clinical responses in the bacteriologic eligible population at the OT,
TOC, LTFU, and EOS visits, for all children, and for the two age
groups (24 months, >24 months). Clinical cure rates at the TOC
visit for all children in the azithromycin ER and amoxicillin/
clavulanate groups were 80.2% and 84.5%, respectively (differ-
ence - 3.9%; 95% CI -10.4, 2.6) (Table 3 and Fig. 2).
3.4. Clinical response by baseline pathogen
Clinical responses at the TOC visit by pathogen in bacteriologic
eligible children are shown in Table 4. In children with infections
caused by S. pneumoniae, overall clinical cure rates were lower in
Table 1
Baseline demographic characteristics and prognostic factors (all-treated children)a.
Parameter AZM
(n=450)
AMC
(n=452)
Age
24 months 294 (65.3) 299 (66.2)
>24 months 156 (34.7) 153 (33.8)
Mean (range) 20.9 (2–47) 20.7 (3–47)
Weight (kg), mean  SD 11.73.2 11.73.4
Height (cm), mean SD 82.111.6 81.711.6
History of AOM (not including current
episode)
348 (77.3) 370 (81.9)
Recurrent 157 (34.9) 165 (36.5)
Persistent 30 (6.7) 20 (4.4)
Both 98 (21.8) 102 (22.6)
Severe bulging of tympanic membraneb
Left ear 194 (43.1) 174 (38.5)
Right ear 222 (49.3) 222 (49.1)
Antibiotics for AOM within 90 days
of baseline
278 (61.8) 295 (65.3)
First episode in ﬁrst 6 months of life 146 (32.4) 159 (35.2)
Exposure to tobacco smoke 119 (26.4) 129 (28.5)
Daycare attendance 184 (40.9) 158 (35.0)
Children aged 8 years in household 321 (71.3) 339 (75)
Sibling with history of AOM 111 (24.7) 135 (29.9)
History of asthma/wheezing 104 (23.1) 113 (25)
Received pneumococcal vaccine 107 (23.8) 95 (21.0)
Received inﬂuenza vaccine 36 (8) 35 (7.7)
Breastfed for 3 months 315 (70) 313 (69.2)
Current paciﬁer use 128 (28.4) 127 (28.1)
AOM, acute otitis media; AZM, extended-release azithromycin; AMC, amoxicillin/
clavulanate; SD, standard deviation.
a Values are No. of children (%), unless otherwise speciﬁed.
b Includes patients with a perforated tympanic membrane draining purulent
material, who were classed as having severe bulging of the tympanic membrane as
per the study protocol.
Table 2
Summary of baseline pathogens (all-treated children).
AZM
(n=450)
AMC
(n=452)
Total
(N=902)
No. (%) of patients with pathogen 282 (62.7) 283 (62.6) 565 (62.6)
Total (%) with single pathogen 233 (51.8) 240 (53.1) 473 (52.4)
Total (%) with multiple pathogens 49 (10.9) 43 (9.5) 92 (10.2)
Total No. of pathogensa 337 333 670
H. inﬂuenzae 133 126 259
b-Lactamase-positive 23 26 49
b-Lactamase-negative 110 100 210
S. pneumoniaeb 120 111 231
Penicillin-susceptible 71 73 144
Penicillin-intermediate 36 19 55
Penicillin-resistant 12 19 31
M. catarrhalis 30 30 60
b-Lactamase-positive 29 29 58
b-Lactamase-negative 1 1 2
S. pyogenes 18 13 31
S. aureus 9 18 27
Oxacillin-susceptible 9 16 25
Oxacillin-resistant 0 2 2
AZM, extended-release azithromycin; AMC, amoxicillin/clavulanate.
a A child may have had more than one pathogen isolated.
b One isolate in the azithromycin ER arm was not tested for penicillin
susceptibility at the central laboratory. Therefore, the sum of the No. of isolates
in the penicillin susceptibility categories is less than the total No. of isolates for this
pathogen.
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clavulanate group (77.9% vs. 88.5%; p = 0.047). However, the
differences were not statistically signiﬁcant when categorized by
susceptibility to penicillin and/or by age. Similar clinical cure rates
were observed among children with baseline penicillin-suscepti-
ble S. pneumoniae, regardless of age (86.4% vs. 91.3%, respectively;
p = 0.419).
Clinical cure rates at the TOC visit by geographic region and
treatment-speciﬁc susceptibility are shown in Table 5. Within theTable 3
Clinical cure rates in bacteriologic eligible children (all study visits).
Study visit No. of children with clinical
population (%)
AZM
On therapy (day 4–6)
All children 228/258 (88.4)
24 months 155/180 (86.1)
>24 months 73/78 (93.6)
Test of cure (day 12–14)
All children 207/258 (80.2)
24 months 139/180 (77.2)
>24 months 68/78 (87.2)
Long-term follow-up (day 28–32)b
All children 184/202 (91.1)
24 months 118/134 (88.1)
>24 months 66/68 (97.1)
End of study (day 41–64)c
All children 74/79 (93.7)
24 months 53/57 (93.0)
>24 months 21/22 (95.5)
AZM, extended-release azithromycin; AMC, amoxicillin/clavulanate; CI, conﬁdence inte
a Difference in cure rates between treatment groups, adjusted for age.
b Includes children who were cured at the TOC visit and had an LTFU assessment.
c Includes children who were cured at the LTFU visit and had an EOS assessment (twNorth American region, across all ages, there was essentially no
difference in the clinical cure rates of 66.7% for azithromycin ER
and 68.4% for amoxicillin/clavulanate. In contrast, within the Latin
American region, for all ages, the cure rates were 81.1% and 93.4%,
respectively. More children in North America received azithro-
mycin ER (n = 27) than received amoxicillin/clavulanate (n = 19).
Of note, the S. pneumoniae cure rates for susceptible organisms
among children 24 months of age were low for both treatment
groups in North America: 9/14 (64.3%) for azithromycin ER and 8/
13 (61.5%) for amoxicillin/clavulanate. This may be due in part to
the four azithromycin-treated children deemed automatic failures
on day 1, all of whom had S. pneumoniae (three of whom had
susceptible S. pneumoniae) and the two amoxicillin/clavulanate-
treated children deemed automatic failures on day 1 (one with
susceptible S. pneumoniae; one with M. catarrhalis). Of these sixsuccessb/total p-Value Difference % (95% CI)a
AMC
221/239 (92.5) 0.131 -4.1 (-9.4, 1.2)
147/162 (90.7) 0.238 -4.6 (-11.6, 2.8)
74/77 (96.1) 0.719 -2.5 (-10.9, 5.4)
202/239 (84.5) 0.240 -3.9 (-10.4, 2.6)
133/162 (82.1) 0.285 -4.9 (-13.4, 3.9)
69/77 (89.6) 0.803 -2.4 (-13.1, 8.2)
170/190 (89.5) 0.612 1.6 (-4.5, 7.8)
110/124 (88.7) 1.00 -0.7 (-8.7, 7.5)
60/66 (90.9) 0.162 6.2 (-2.3, 16.4)
60/66 (90.9) 0.548 2.8 (-6.6, 13.0)
43/48 (89.6) 0.729 3.4 (-7.9, 16.4)
17/18 (94.4) 1.00 1.0 (-18.0, 23.6)
rval; TOC, test of cure; LTFU, long-term follow-up; EOS, end of study.
o study sites).
Fig. 2. Clinical cure rates at the test-of-cure visit (day 12–14) in all study
populations (95% CI) (AZM, extended-release azithromycin; AMC, amoxicillin/
clavulanate).
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secondary to vomiting within 30 min of dosing (see below).
Outside of North America, lower S. pneumoniae cure rates were
driven by nonsusceptible organisms, especially for childrenTable 5
Clinical cure rates at the test-of-cure visit (day 12–14) in bacteriologic eligible childre
treatment-speciﬁc susceptibility.
Study group No. children cured/total No. of ch
Worldwide L
AZMa
Total (all ages) 88/113 (77.9) 6
24 months 65/86 (75.6) 4
Azithromycin-susceptible 52/65 (80) 4
Azithromycin-nonsusceptible 13/21 (61.9) 7
>24 months 23/27 (85.2) 1
Azithromycin-susceptible 21/24 (87.5) 1
Azithromycin-nonsusceptible 2/3 (66.7) 1
AMC
Total (all ages) 92/104 (88.5) 7
24 months 61/71 (85.9) 4
Amoxicillin-susceptible 59/68 (86.8) 4
Amoxicillin-nonsusceptible 2/3 (66.7) 1
>24 months 31/33 (93.9) 2
Amoxicillin-susceptible 30/32 (93.8) 2
Amoxicillin-nonsusceptible 1/1 (100) 1
AZM, extended-release azithromycin; AMC, amoxicillin/clavulanate.
a Fifteen children were infected with both azithromycin-susceptible S. pneumoniae a
Table 4
Clinical cure rates at the test-of-cure visit (day 12–14) in bacteriologic eligible childre
AZM
All ages 24 months >
Total pathogens 223/277 (80.5) 153/197 (77.7) 70
H. inﬂuenzae 97/121 (80.2) 65/86 (75.6) 32
b-Lactamase-positive 14/21 (66.7) 11/16 (68.8) 3/
b-Lactamase-negative 83/100 (83) 54/70 (77.1) 29
S. pneumoniae 88/113 (77.9) 65/86 (75.6) 23
Penicillin-susceptibleb 57/66 (86.4) 41/48 (85.4) 16
Penicillin-intermediateb 26/35 (74.3) 19/27 (70.4) 7/
Penicillin-resistantb 5/11 (45.5) 5/11 (45.5) 0/
M. catarrhalis 25/29 (86.2) 16/18 (88.9) 9/
b-Lactamase-positive 24/28 (85.7) 16/18 (88.9) 8/
b-Lactamase-negative 1/1 (100) NA 1/
S. pyogenes 13/14 (92.9) 7/7 (100) 6/
AZM, extended-release azithromycin; AMC, amoxicillin/clavulanate; NA, not available;
a Children may have had more than one pathogen at baseline.
b Penicillin-sensitive, MIC 0.06mg/ml; penicillin-intermediate, MIC 0.125–1.0mg/mreceiving azithromycin ER. Of 24 children with ANSSP, 13 were
in Latin America; of these, 12were24months old. This group had
the lowest azithromycin ER cure rate (7/12; 58.3%). In contrast,
therewere only four amoxicillin/clavulanate-treated childrenwith
amoxicillin-nonsusceptible S. pneumoniae, three of whom were
cured.
Finally, of the children who had a clinical cure at TOC and then
had a follow-up tympanocentesis at subsequent visits due to
clinical failure, superinfection occurred in 10 of 15 children in the
azithromycin ER group and in 9 of 14 children in the amoxicillin/
clavulanate group. Of note, four children in the azithromycin ER
group and three children in the amoxicillin/clavulanate treatment
group were infected with a different strain of S. pneumoniae at the
LTFU or EOS visits, compared with those obtained at earlier visits.
This was conﬁrmed through PFGE testing. Susceptibility testing
showed that MIC concentrations had not changed by more than 1
log2 dilution (within experimental error) between strains obtained
before and after treatment. Therefore, among S. pneumoniae
isolates, there was no evidence of the development of antimicro-
bial resistance during the course of this study.
3.5. Bacteriologic response
Table 6 shows the overall bacteriologic eradication rates, aswell
as the eradication rates by baseline pathogen, at the OT visit in then with infections caused by Streptococcus pneumoniae, by geographic region and
ildren (%)
atin America North America Europe
0/74 (81.1) 18/27 (66.7) 10/12 (83.3)
7/59 (79.7) 13/20 (65) 5/7 (71.4)
0/47 (85.1) 9/14 (64.3) 3/4 (75)
/12 (58.3) 4/6 (66.7) 2/3 (66.7)
3/15 (86.7) 5/7 (71.4) 5/5 (100)
2/14 (85.7) 5/6 (83.3) 4/4 (100)
/1 (100) 0/1 (0) 1/1 (100)
1/76 (93.4) 13/19 (68.4) 8/9 (88.9)
6/50 (92) 9/15 (60) 6/6 (100)
5/49 (91.8) 8/13 (61.5) 6/6 (100)
/1 (100) 1/2 (50) 0/0 (0)
5/26 (96.2) 4/4 (100) 2/3 (66.7)
4/25 (96) 4/4 (100) 2/3 (66.7)
/1 (100) 0/0 (0) 0/0 (0)
nd H. inﬂuenzae; 12 (80%) were clinical cures.
n by baseline pathogena.
AMC
24 months All ages 24 months >24 months
/80 (87.5) 220/260 (84.6) 149/180 (82.8) 71/80 (88.8)
/35 (91.4) 95/116 (81.9) 66/82 (80.5) 29/34 (85.3)
5 (60) 22/25 (88) 17/20 (85) 5/5 (100)
/30 (96.7) 74/92 (80.4) 50/63 (79.4) 24/29 (82.8)
/27 (85.2) 92/104 (88.5) 61/71 (85.9) 31/33 (93.9)
/18 (88.9) 63/69 (91.3) 41/45 (91.1) 22/24 (91.7)
8 (87.5) 17/19 (89.5) 12/14 (85.7) 5/5 (100)
0 (0) 13/17 (76.5) 9/13 (69.2) 4/4 (100)
11 (81.8) 21/27 (77.8) 15/19 (78.9) 6/8 (75)
10 (80) 21/26 (80.8) 15/19 (78.9) 6/7 (85.7)
1 (100) 0/1 (0) NA 0/1 (0)
7 (85.7) 12/13 (92.3) 7/8 (87.5) 5/5 (100)
MIC, minimum inhibitory concentration.
l; penicillin-resistant, MIC 2mg/ml.
Table 6
Bacteriologic eradication rates at the on-therapy (OT) visit (day 4–6) in bacteriologic OT childrena.
AZM AMC
All ages 24 months >24 months All ages 24 months >24 months
Total pathogens 109/132 (82.6) 79/99 (79.8) 29/32 (90.6) 92/100 (92) 68/76 (89.5) 24/24 (100)
H. inﬂuenzae 42/54 (77.8) 30/41 (73.2) 12/13 (92.3) 37/44 (84.1) 31/38 (81.6) 6/6 (100)
b-Lactamase-positive 3/4 (75) 2/3 (66.7) 1/1 (100) 5/6 (83.3) 5/6 (83.3) 0/0 (0)
b-Lactamase-negative 39/50 (78) 28/38 (73.7) 11/12 (91.7) 32/38 (84.2) 26/32 (81.3) 6/6 (100)
S. pneumoniae 45/54 (83.3) 38/46 (82.6) 7/8 (87.5) 47/48 (97.9) 30/31 (96.8) 17/17 (100)
Penicillin-susceptibleb 29/29 (100) 24/24 (100) 5/5 (100) 29/29 (100) 19/19 (100) 10/10 (100)
Penicillin-intermediateb 15/20 (75) 13/18 (72.2) 2/2 (100) 7/8 (87.5) 3/4 (75) 4/4 (100)
Penicillin-resistantb 1/4 (25) 1/4 (25) 0/0 (0) 11/11 (100) 8/8 (100) 3/3 (100)
M. catarrhalis 14/14 (100) 8/8 (100) 6/6 (100) 4/4 (100) 4/4 (100) 0/0 (0)
b-Lactamase-positive 14/14 (100) 8/8 (100) 6/6 (100) 4/4 (100) 4/4 (100) 0/0 (0)
b-Lactamase-negative NA NA NA NA NA NA
S. pyogenes 7/9 (77.8) 3/4 (75) 4/5 (80) 4/4 (100) 3/3 (100) 1/1 (100)
AZM, extended-release azithromycin; AMC, amoxicillin/clavulanate; MIC, minimum inhibitory concentration.
a Performed in 116 children treated with azithromycin and 93 children treated with amoxicillin/clavulanate; children may have had more than one pathogen at baseline.
b Penicillin-sensitive, MIC 0.06mg/ml; penicillin-intermediate, MIC 0.125–1.0mg/ml; penicillin-resistant, MIC 2mg/ml.
Table 7
Bacteriologic outcome at the on-therapy visit (day 4–6) versus clinical response at the test-of-cure visit (day 12–14)a.
AZM (No. of children) AMC (No. of children)
Clinical success Clinical failure Total Clinical success Clinical failure Total
Bacteriologic success 91 11 102 79 12 91
Bacteriologic failure 12 10 22 4 4 8
Total 103 21 124 83 16 99
AZM, extended-release azithromycin ER; AMC, amoxicillin/clavulanate.
a Includes children in the bacteriologic on-therapy population with non-missing clinical responses at the test-of-cure visit (day 12–14) (two study sites).
Table 8
Treatment-related adverse events occurring at an incidence of >1% in either
treatment group.
Adverse event AZM (n=450) No. (%) AMC (n=452) No. (%)
Abdominal pain 11 (2.4) 7 (1.5)
Fever 7 (1.6) 4 (0.9)
Anorexia 10 (2.2) 9 (2.0)
Diarrhea 42 (9.3) 80 (17.7)a
Nausea 2 (0.4) 6 (1.3)
Loose stools 42 (9.3) 58 (12.8)
Vomiting 48 (10.7) 37 (8.2)
Irritability 2 (0.4) 5 (1.1)
Somnolence 4 (0.9) 5 (1.1)
Respiratory tract infection 3 (0.7) 6 (1.3)
Dermatitis 7 (1.6) 23 (5.1)b
Fungal dermatitis 4 (0.9) 15 (3.3)
Rash 23 (5.1) 35 (7.7)
AZM, extended-release azithromycin; AMC, amoxicillin/clavulanate.
a p=0.002.
b p=0.004.
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tympanocentesis at two study sites). In both treatment groups,
eradication rates were slightly higher in the older age group. The
eradication rate across all ages was 82.6% in the azithromycin ER
group and 92% in the amoxicillin/clavulanate group (p = 0.050).
Eradication rates were similar for H. inﬂuenzae. Eradication rates
were also similar for M. catarrhalis and S. pyogenes, although the
numbers may be too small for adequate comparison. Eradication
rates were lower in the azithromycin ER group than in the
amoxicillin/clavulanate group for S. pneumoniae (83.3% vs. 97.9%,
p = 0.018). All penicillin-susceptible isolates were eradicated in
both groups. All 11 penicillin-resistant S. pneumoniae isolates in
the amoxicillin/clavulanate arm were eradicated.
3.6. Correlation of bacteriologic eradication and clinical efﬁcacy
The relationship between bacteriologic response at the OT visit
and clinical response at the TOC visit is shown in Table 7. In
children in the azithromycin ER group, 10.8% (11/102) with
bacterial eradication at OT had clinical failure at TOC, versus 13.1%
(12/91) in the amoxicillin/clavulanate group. In children in the
azithromycin ER and amoxicillin/clavulanate groups with bacteri-
ologic persistence at OT, 45.5% (10/22) and 50% (4/8), respectively,
were classiﬁed as a clinical failure at the TOC visit. Bacteriologic
response at the OT visit was associatedwith clinical response at the
TOC visit (p < 0.0001, overall odds ratio (OR) = 6.80).
3.7. Safety
Overall, AEs occurred in 56% of children treated with
azithromycin ER and in 62.2% of children treated with amoxicil-
lin/clavulanate. Most AEs were of mild to moderate severity. In the
azithromycin ER group, three serious AEs were reported versus
seven serious AEs in the amoxicillin/clavulanate group; one of
these (severe rash in a patient in the amoxicillin/clavulanate
group) was considered to be related to treatment.The most frequently reported treatment-related AEs are shown
in Table 8. The overall treatment-related AE burden was 35.0 AE
days/patient-year for azithromycin ER and 64.1 AE days/patient-
year for amoxicillin/clavulanate.
Treatment-related vomiting was reported at a rate of 10.7% in
children receiving azithromycin ER and 8.2% in those receiving
amoxicillin/clavulanate. Overall, children receiving azithromycin ER
had a higher rate of early vomiting, deﬁned as onset on day 1,
particularly within the ﬁrst 5 min of dosing, compared with children
receiving amoxicillin/clavulanate (7.3% vs. 1.3%). However, azithro-
mycinER-treated childrenhada lower rate of late vomiting relative to
amoxicillin/clavulanate-treated children, including onset of vomiting
after day 1 (2.7% vs. 6.2%, respectively) and duration of vomiting
exceeding 1 day (1.6% vs. 3.8%). Vomiting rates were similar in both
treatment groups for children aged 24 months (9.5% vs. 9.4%). For
childrenaged>24months, the rateofvomitingwashigher inchildren
in the azithromycin ER group than in the amoxicillin/clavulanate
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amoxicillin/clavulanate-treated children, the AE burden for treat-
ment-related vomiting was higher than that for azithromycin ER-
treated children (2.4 vs. 1.4 AE days/patient-year).
4. Discussion
In this study, a single dose of azithromycin ER was non-inferior
to a 10-day regimen of twice daily amoxicillin/clavulanate in the
treatment of AOM in children with, or at risk for, recurrent or
persistent AOM.Non-inferiority required the lower limit of the 95%
CI around the difference in the primary endpoint (azithromycin
minus amoxicillin/clavulanate) to be greater than -10%. Among all
study populations, the lower limit of the 95% CI around the
difference ranged from -10.4% (bacteriologic eligible population)
to -6.7% (clinical per protocol population; Fig. 2). In the
bacteriologic per protocol population-the population typically
used in AOM efﬁcacy studies with middle ear ﬂuid cultures-the
lower limit was -9.1%. Although amoxicillin/clavulanate appeared
slightly more effective at the earlier visits (OT and TOC),
azithromycin ER appeared slightly more effective at the later
visits (LTFU and EOS).
In the current study, per-pathogen clinical cure rates at the TOC
visit were similar in both treatment groups for H. inﬂuenzae, M.
catarrhalis, S. pyogenes, and penicillin-susceptible S. pneumoniae. Of
note, clinical cure rates in the azithromycin ER group for infections
caused byH. inﬂuenzaewere higher in this study than in a previous
study in a comparable high-risk population that compared a 3-day
regimen of 60-mg/kg per day of conventional azithromycin (i.e.,
azithromycin immediate release) with a 10-day regimen of
amoxicillin/clavulanate 90/6.4 mg/kg per day.7 An earlier study
comparing azithromycin with amoxicillin/clavulanate (same dose
administered in this study) has also shown lower H. inﬂuenzae-
speciﬁc cure rates using a lower total azithromycin dose (30 mg/
kg), given as either a single dose or divided over 3 or 5 days.22
Clinical cure rates were lower in children aged 24 months
relative to those older than 24 months, in both treatment groups.
Within the younger age group, clinical cure rates were slightly
lower for azithromycin ER. It appears that the higher frequency of
middle ear infections caused by ANSSP, and the lower cure rate for
azithromycin ER versus this organism, particularly among Latin
American children 24 months of age, accounts for the difference
in S. pneumoniae clinical efﬁcacy-and hence overall clinical
efﬁcacy-when comparing azithromycin ER to amoxicillin/clavula-
nate in the bacteriologic evaluable populations.
S. pneumoniae serotypes differed considerably across the Latin
American and North American regions. Nearly all of the children
enrolled fromNorth America had been vaccinatedwith the 7-valent
pneumococcal conjugate vaccine, in contrast to none of the children
from Latin America. We speculate that there may be differences in
virulence among these serotypes that areworking independently of
susceptibility to the study drugs. Speciﬁcally, in the USA, 19% of
isolates were serotype 19A, 15% were 19F, 15% were 3, and 4%were
23F. In Costa Rica and Chile, 16% were serotype 19F, 14% were 6B,
13% were 3, 12% were 14, and 8% were 23F.
Of the 14 S. pneumoniae isolates classiﬁed as serotype 19A, nine
were from North America and ﬁve were from Latin America. Overall,
11 of 14 strains were sensitive to azithromycin. Of the three
azithromycin-resistant strains (MIC 4, >256, and >256mg/ml,
respectively), all were from the USA: two from eastern Virginia
and one from western Pennsylvania. The two strains with MICs
>256mg/ml had both the ermB andmef genes and were resistant to
penicillin (MIC 4mg/ml). The other azithromycin-resistant strain had
mef and ermAbutwasnot resistant topenicillin.Of note, oneUS strain
resistant to penicillin (MIC 2mg/ml) was susceptible to azithromycin
(MIC 0.5mg/ml). Five of the serotype 19A strains were from LatinAmerica (two from Chile and one each from the Dominican Republic,
Mexico, and Panama), and all were susceptible to azithromycin (MIC
0.06–0.12mg/ml) and penicillin (MIC 0.03–0.25mg/ml).
Because serotype 19A is covered by the new 13-valent
pneumococcal conjugate vaccine, there should be a decrease in
pneumococcal disease caused by this serotype. However, similar to
the 7-valent vaccine, one could reasonably assume that after
several years of use, replacement in the population of the six newly
represented serotypes (including 19A) will occur, resulting in
pneumococcal disease from other, currently less common,
serotypes. In addition, an even greater proportion of AOM may
be caused by non-pneumococcal organisms, such as H. inﬂuenzae
and S. pyogenes. Of note, H. inﬂuenzae was the most common
organism identiﬁed in this large bacteriologic study, and S.
pyogenes was the fourth most common.
Overall, bacteriologic response at the OT visit is associated with
clinical response at the TOC visit (overall OR = 6.80; p < 0.0001).
Agreement between clinical success at TOC and bacterial eradica-
tion at OT was high in the azithromycin ER and amoxicillin/
clavulanate groups (83.0% and 83.8%, respectively) and slightly
elevated compared to the 76% value reported by Dagan et al.22
In this study, the overall AE proﬁle of azithromycin ERwasmore
favorable than that of amoxicillin/clavulanate, primarily due to the
increased AE burden for treatment-related diarrhea, loose stools,
rash, and vomiting in children receiving amoxicillin/clavulanate.
Signiﬁcantly higher rates of dermatitis and diarrhea were reported
in the amoxicillin/clavulanate group. Children receiving azithro-
mycin ER had a higher rate of early vomiting, while children
receiving amoxicillin/clavulanate had a higher rate of late
vomiting, as well as increased duration of vomiting, resulting in
a greater overall burden of vomiting.
Early vomitingmay have an impact on efﬁcacy. In this study, the
primary analysis dictated that missing outcomes be classiﬁed as
failures. There weremore early vomiters on azithromycin andmore
late vomiters on amoxicillin/clavulanate. A vomiter within minutes
of dosing would more likely be deemed by the investigator as being
at risk of not receiving appropriate therapy because of the 50%
chanceofbeing randomized to single-dose azithromycin, in contrast
tooneof 20potential doses of amoxicillin/clavulanate. The subject is
theoreticallymoreat riskof treatment failure, andhence,more likely
tobediscontinued andplacedonalternative therapy. This is not true
of late vomiters, because these children, at the time of vomiting,
would either have already received a full course of single-dose
azithromycin or vomited just one of 20 doses of amoxicillin/
clavulanate; in either case there is little risk of treatment failure and
less likelihood of discontinuation.
Early vomiters may also have an effect on the assessment of
compliance in this study, because the ﬁrst dose is given in the clinic
and is therefore directly observed, and because the ﬁrst dose
contains both active drug and placebo, and hence extra volume,
compared to other doses. An early vomiter who does not complete
the ﬁrst dose is therefore more likely than a late vomiter to be
considerednoncompliant.Nevertheless,despitehigher ratesofearly
vomiting, all azithromycin-treated children were compliant with
their treatment regimens, while compliance ratesweremuch lower
in amoxicillin/clavulanate-treated children. Of note, in a previous
study, early vomiting (i.e.< 60 min post-dose) after administration
ofa singledoseofazithromycinERdidnotappear tonegativelyaffect
clinical cure rates in young children with AOM.32
Compliance with study treatment was signiﬁcantly higher in the
azithromycin ER group than in the amoxicillin/clavulanate group
(100% vs. 77%). One hundred percent compliance removes noncom-
pliance as a risk factor for the development (i.e., selection) of
resistance.
Based on data from the current trial, the MIC90 for penicillin was
0.25mg/ml in Costa Rica vs. 2mg/ml in the USA and Chile. It is
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of enrolled children fromthe LatinAmerican region, 70% fewer strains
of S. pneumoniaewere isolated than in Costa Rica. This suggests that
risk factors for penicillin resistance, such as the widespread use ofb-
lactamantibiotics and/or dissemination of penicillin-resistant clones,
may be at play in these regions, relative to Costa Rica.
It has been suggested that the long elimination half-life of
azithromycin may give rise to subinhibitory concentrations in the
upper respiratory tract post-treatment,whichmay promote selective
resistance. Despite this, this study showed that clinical responses
were sustained at the LTFU visit andwere numerically similar in both
treatment groups. PFGE and serotype analyses of results of follow-up
tympanocentesesdemonstrated thatchildrenwhowerebacteriologic
failures at follow-up visitswere as likely to be infectedwith the same
persistentpathogenaswithadifferent species of pathogen, indicating
anew infection.Whenpersistent strainswere tested for antimicrobial
susceptibility, results were not changed from baseline. Due to the
relatively limited number of patients enrolled in this trial, we cannot
draw any deﬁnite conclusions on the development of azithromycin
resistance in thesepatients; this questionwill have tobe answeredby
future surveillance studies. However, results of earlier studies with
azithromycin suggest that any selection for azithromycin resistance
in nasopharyngeal/oropharyngeal pathogens could be delayed by use
of a single dose.32–35
In conclusion, single-dose azithromycin ER provides near
equivalent effectiveness to multiple days of amoxicillin/clavula-
nate for the treatment of children with AOM who have, or are at
risk for, recurrent or persistent middle ear infection.
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